Your session is about to expire
← Back to Search
This trial is testing a new drug, YL-13027, to see if it is safe and effective in patients with advanced solid tumors. The first part of the trial (phase Ia) is to determine the best dose of the drug (RP2D) by giving it to a small group of patients. The second part of the trial (phase II) is to expand the study to a larger group of patients to see if the drug has any preliminary anti-tumor activity.
- Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Group 1: YL-13027
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum amount of participants that can take part in this research?
"Affirmative. According to clinicaltrials.gov, this study is actively looking for patients - it was first published on May 17th 2022 and most recently edited on the 16th of the same month. 54 people are needed across a single site in order to complete the trial."
What potential risks come with the use of YL-13027?
"Given the dearth of data on YL-13027's safety and efficacy, we at Power have rated this experimental medication a 1."
Is enrollment available for this experimental treatment?
"Yes, the information posted on clinicaltrials.gov implies that this trial is still open to applicants. Initially listed on May 17th 2022 and updated most recently on the 16th of May, it requires 54 patients from a single medical centre."
Share this study with friends